Literature DB >> 16675556

Chk2 molecular interaction map and rationale for Chk2 inhibitors.

Yves Pommier1, John N Weinstein, Mirit I Aladjem, Kurt W Kohn.   

Abstract

To organize the rapidly accumulating information on bioregulatory networks related to the histone gamma-H2AX-ATM-Chk2-p53-Mdm2 pathways in concise and unambiguous diagrams, we used the molecular interaction map notation (http://discover.nci.nih.gov/min). Molecular interaction maps are particularly useful for networks that include protein-protein binding and posttranslational modifications (e.g., phosphorylation). Both are important for nearly all of the proteins involved in DNA double-strand break signaling. Visualizing the regulatory circuits underlying cellular signaling may help identify key regulatory reactions and defects that can serve as targets for anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16675556     DOI: 10.1158/1078-0432.CCR-06-0743

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  39 in total

Review 1.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

2.  Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.

Authors:  George T Lountos; Andrew G Jobson; Joseph E Tropea; Christopher R Self; Guangtao Zhang; Yves Pommier; Robert H Shoemaker; David S Waugh
Journal:  J Struct Biol       Date:  2011-09-22       Impact factor: 2.867

3.  Bocavirus infection induces a DNA damage response that facilitates viral DNA replication and mediates cell death.

Authors:  Yong Luo; Aaron Yun Chen; Jianming Qiu
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

4.  CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.

Authors:  Victoria E Anderson; Michael I Walton; Paul D Eve; Katherine J Boxall; Laurent Antoni; John J Caldwell; Wynne Aherne; Laurence H Pearl; Antony W Oliver; Ian Collins; Michelle D Garrett
Journal:  Cancer Res       Date:  2011-01-15       Impact factor: 12.701

5.  Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.

Authors:  Sheena M Aris; Yves Pommier
Journal:  Cancer Res       Date:  2011-12-21       Impact factor: 12.701

6.  CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute.

Authors:  G Zoppoli; S Solier; W C Reinhold; H Liu; J W Connelly; A Monks; R H Shoemaker; O D Abaan; S R Davis; P S Meltzer; J H Doroshow; Y Pommier
Journal:  Oncogene       Date:  2011-07-18       Impact factor: 9.867

7.  Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.

Authors:  George T Lountos; Joseph E Tropea; Di Zhang; Andrew G Jobson; Yves Pommier; Robert H Shoemaker; David S Waugh
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

8.  Death receptor-induced activation of the Chk2- and histone H2AX-associated DNA damage response pathways.

Authors:  Stéphanie Solier; Olivier Sordet; Kurt W Kohn; Yves Pommier
Journal:  Mol Cell Biol       Date:  2008-10-27       Impact factor: 4.272

9.  Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.

Authors:  YanGuo Kong; Gustavo A Barisone; Ranjit S Sidhu; Robert T O'Donnell; Joseph M Tuscano
Journal:  Mol Med       Date:  2015-08-24       Impact factor: 6.354

10.  CellMiner: a relational database and query tool for the NCI-60 cancer cell lines.

Authors:  Uma T Shankavaram; Sudhir Varma; David Kane; Margot Sunshine; Krishna K Chary; William C Reinhold; Yves Pommier; John N Weinstein
Journal:  BMC Genomics       Date:  2009-06-23       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.